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Inflammation is known to participate in the mediation of
a growing number of acute and chronic neurological
disorders. Even so, the involvement of inflammation in the
pathogenesis of epilepsy and seizure-induced brain damage
has only recently been appreciated. Inflammatory processes,
including activation of microglia and astrocytes and produc-
tion of proinflammatory cytokines and related molecules,
have been described in human epilepsy patients as well as in
experimental models of epilepsy. For many decades, a
functional role for brain inflammation has been implied by
the effective use of anti-inflammatory treatments, such as
steroids, in treating intractable pediatric epilepsy of diverse
causes. Conversely, common pediatric infectious or autoimmune
diseases are often accompanied by seizures during the course
of illness. In addition, genetic susceptibility to inflammation
correlated with an increased risk of epilepsy. Mounting
evidence thus supports the hypothesis that inflammation may
contribute to epileptogenesis and cause neuronal injury in
epilepsy. We provide an overview of the current knowledge
that implicates brain inflammation as a common predisposing
factor in epilepsy, particularly childhood epilepsy.
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Epilepsy is a neurologic condition of diverse
etiologies that affects about 1% of the global
population.
1 Approximately 325,000 children from
5 to 14 years of age have active epilepsy, and the
majority of adults with epilepsy experience
childhood onset of seizures.
2 The median age of
seizure onset is between 5 and 6 years.
3 A single
unprovoked seizure during childhood is common,
occurring in 4 - 10% of children.
4 Children in their
first year of life, particularly, are at the highest
risk for developing epilepsy.
Although the central nervous system (CNS)
used to be considered an immunoprivileged system
due to the presence of the blood-brain barrier
(BBB), graft acceptance, a lack of conventional
lymphatic drainage, and relatively low levels of
monocytes and lymphocytes, it is becoming clear
that immune and inflammatory reactions do
occur in the CNS, either intrinsically from the
brain itself or acquired from systemic circulation
through a damaged BBB. While the role of
inflammation in the pathophysiology of human
epilepsy remains hypothetical, inflammatory and
immune reactions in the brains do occur in
human epilepsy patients and in experimental
models of epilepsy.
Acute inflammatory reaction after seizures has
long been suspected due to clinical observation
of pleocytosis, without any evidence of infection,
in the cerebrospinal fluid (CSF) and peripheral
blood of patients with recent generalized convul-
sions. Steroids or adrenocorticotropic hormone
(ACTH), with a suppressive effect on inflamma-
tion or immune reactions, have been used to
effectively treat children with intractable epilepsy.
Various common pediatric infectious or autoim-
mune diseases are often heralded by seizures at
the onset or accompanied by seizures during the
course of the illness.
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INFLAMMATION IS IMPLICATED IN
CHILDHOOD NEUROLOGICAL DISEASES
ACCOMPANIED BY SEIZURES
Damaged BBB in CNS injury and delayed onset
of epilepsy
The BBB consists of morphologically nonin-
festrated endothelial cells with interendothelial
tight junctions, and its maintenance depends on
normal functioning of pericytes, perivascular
microglia, astrocytes, and the basal lamina. Under
normal conditions, the BBB protects the CNS by
regulating the entry of plasma-born substances
and immune cells.
5 Astrocytes are thought to act
as important regulators of the balance between
endothelial stability and permeability of the BBB.
A high transendothelial barrier can be reintro-
duced in human or bovine endothelial cell
monolayers cultured in astrocyte-conditioned
media, suggesting that astrocyte-derived soluble
factors may contribute BBB characteristics to
endothelial cells.
6 Transient changes have been
demonstrated in the physiology and structures of
the BBB in various CNS injuries such as status
epilepticus, infections, and traumatic and ischemic
events.
5 An impaired BBB and inflammatory state
are common features of neurological diseases
associated with the late onset of epilepsy.
7 Proin-
flammatory cytokines are elevated in experimental
animal brains after ischemia
8 and in the CSF from
stroke
9 and epilepsy
10 patients. Cytokine release
causes subsequent up-regulation of endothelial
and neutrophil adhesion molecules in human
cerebrovascular endothelial cells during hypoxic
injury,
11 leading to transmigration of leukocytes
across the endothelium and the BBB. Leukocyte
recruitment may trigger signal transduction cas-
cades, resulting in tight junction disorganization
and BBB breakdown. Although the mechanism of
delayed onset of epilepsy remains unclear,
available data suggest that inflammation and
breakdown of the BBB are necessary components
of epileptogenesis following brain injury. Further
work is needed to determine whether BBB
breakdown is a pre-requisite for future develop-
ment of epilepsy and to elucidate the potential for
prophylactic treatment during the latent period
following an injury to prevent epilepsy.
Childhood noninfectious neurological diseases
associated with the late onset of epilepsy
Neonatal and childhood stroke
The incidence of arterial ischemic stroke and
cerebral sinovenous thrombosis has increased to 2
to 6 per 100,000 children a year during the past
10 years.
12 Even in neonates, stroke affects as
many as 1 in every 4000 live births.
13 Common
risk factors include congenital heart disease and
sickle cell disease. Stroke in infancy and child-
hood adversely affects development; neurological
deficits occur in 60% of children and 10 - 25% will
experience recurrent stroke.
14 Treatment is em-
pirically provided with antithrombotic drugs.
In perinatal stroke, neonatal seizures are the
most common clinical symptom. Neonatal seizures
in a setting of arterial stroke are mostly focal and
may occur in the absence of other signs of
neonatal encephalopathy. Of infants with ischemic
cerebral infarcts proven in autopsy studies, 25 -
40% are diagnosed with neonatal seizures.
15 Some
infants with a normal neurological examination in
the neonatal period may be diagnosed in later
months with asymmetry of reach and grasp,
failure to reach developmental milestones, or
post-neonatal seizures.
16 Neonatal seizures and
abnormal neurologic examination at discharge are
two risk factors for later neuro-developmental dis-
abilities and chronic epilepsy.
17 Childhood epilepsy
is a frequent resulting morbidity in perinatal
stroke. In one cohort study of 64 perinatal stroke
patients, 75% of children presented with neonatal
seizures and 67% developed epilepsy after 6
months of age.
18 The median age at onset of
delayed epilepsy was 16 months.
In childhood stroke, seizures commonly occur
acutely and may be the presenting symptom of
stroke. A study of 73 children 17 years old and
younger with acute hemiplegia from stroke found
that 50% of patients had at least one seizure and
29% had recurrent seizures.
19 Time to onset of
delayed seizures and development of epilepsy
ranged from 4 months to more than 10 years in
42 children after unilateral hemispheric stroke.
20
Proinflammatory cytokines IL-1 and IL-6 β
increase in CSF from stroke patients within the
first 24 h after the beginning of symptoms.
21
Systemic injections of progesterone, a neurosteroid,Role of Brain Inflammation in Epileptogenesis
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improve cognitive recovery after stroke and
decrease molecular indicators of neuronal damage
in rats,
22 suggesting immunosuppression as a
possible treatment strategy to prevent late
sequelae.
Autoimmune diseases and epilepsy
a. Systemic Lupus Erythematosus (SLE)
SLE is the most common rheumatic disease in
children.
23 The major organ systems involved in
childhood SLE are similar to adult SLE, but the
frequency of multiple organ involvement and
severity of the disease are greater in children
than adults.
23 General clinical features include
broad variations of rash, arthritis, constitutional
symptoms, renal disease, and cardiovascular,
pulmonary, and neuropsychiatric involvement.
The prevalence of epilepsy in SLE patients is 10-
20%, 8 times higher than in the general
population. Notably, seizures can precede the
diagnosis of SLE, and 5 - 10% of patients experience
seizures several years before the clinical onset of
SLE.
24 This finding suggests that long-term
treatment with antiepileptic drugs may have
precipitated SLE, or alternatively, that epilepsy
and SLE are both manifestations of a genetically
determined predisposition to altered immunity
and inflammatory reaction. Epilepsy in SLE is
significantly associated with anti-phospholipid
antibodies, and the presence of anti-phospholipid
antibodies highly correlates with abnormal MRI
findings of the brain.
24 Patients with anti-phos-
pholipid antibodies are at risk of thromboembolic
manifestations, intrauterine fetal loss, and throm-
bocytopenia, a combination termed anti-phos-
pholipid syndrome. In addition, anti-cardiolipin
antibodies are found in 30 - 60% of SLE patients,
and epilepsy is 3 times more frequent in patients
with anti-cardiolipin antibodies than those
without.
25 These findings raise the possibility that
autoantibodies may trigger seizures and contribute
to epileptogenesis.
b. Hashimoto thyroiditis
Hashimoto thyroiditis is the most common
thyroiditis in children and adults, affecting 1.2%
of school-aged children.
26 Hashimoto encephalo-
pathy is a syndrome associated with high anti-
thyroid antibody titer that can either begin
abruptly, in the form of seizures or agitation, or
develop gradually, in a relapsing-remitting
manner manifested as cognitive deterioration and
psychiatric illness. The occurrence of Hashimoto
encephalopathy is unrelated to the patient's
thyroid function status, and most patients respond
dramatically to corticosteroid therapy.
26 The thera-
peutic efficacy of immunomodulation suggests a
causative role of activated immunity and
autoantibodies for the neurological symptoms in
Hashimoto thyroiditis, including seizures and
epilepsy.
c. Behçet's disease
Behçet's disease is a chronic systemic inflam-
matory disorder of unknown etiology defined by
the classical triad of recurrent oral aphthous,
genital ulcers, and inflammatory eye disease.
The prevalence of CNS disease, often associated
with significant morbidity, varies between 2.9%
and 44%, with male predominance.
27 In 22
patients with neuro-Behçet's disease, 27%
suffered either single or recurrent seizures.
28 CSF
pleocytosis occurred in 50% of patients, and
most showed improvement after immunosup-
pressant therapy.
d. Rasmussen's encephalitis
Rasmussen's encephalitis is a prototype of
inflammatory epilepsy. The autoimmune nature of
this condition was suspected after the discovery of
autoantibodies against glutamate receptor, GluR3,
one of the AMPA ( -3-hydroxy-5-methyl-4- α
isoxazolepropionic acid) subunits. Subsequently,
anti-GluR3 antibodies have been detected in two
other epilepsy syndromes, early-onset noninflam-
matory focal epilepsy and catastrophic infantile
epilepsy.
29 Anti-cardiolipin antibodies, found in
SLE patients, are also found in epilepsy patients,
both adults
30 and children.
31,32 Furthermore, in-
creased levels of anti-nuclear antibodies have been
reported in epilepsy patients.
30 Anti-B2-glyco-
protein I antibodies, specific for thrombosis-
mediated events, have been demonstrated in SLE
patients with epilepsy
33 as well as other epilepsy
patients.
30 Long-term immunotherapy such as
intravenous -globulin and corticosteroids may be γ
beneficial for autoantibody-positive epilepsy
patients.Jieun Choi and Sookyong Koh
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Role of systemic and brain inflammation in
pathogenesis of febrile seizures
Febrile seizures are the most common cause of
seizures in children, affecting 2 to 5% of children.
34
The threshold to febrile seizures is dependent on
the height of the body temperature, but the
threshold varies with individuals and according
to age and maturation.
35 A genetic susceptibility
to inflammation may influence the threshold
convulsive temperature. Seventeen to 30% of
febrile seizure patients have a family history of
febrile seizures.
35 A biallelic polymorphism in the
promoter region of IL-1 at the -511 position that β
can increase IL-1 production occurs more β
frequently in patients with prolonged febrile
convulsions.
36,37 In experimental animals, intrav-
entricular injection of IL-1 reduces the seizure β
threshold in 14-day old mice subjected to
hyperthermia, while IL-1receptor knock-out mice
have higher seizure thresholds, supporting the
role of proinflammatory cytokines in triggering
febrile seizures.
38
Viruses as being increasingly implicated as
causative agents of febrile seizures. Neurotropic
viruses, such as the herpesviruses and influenza
A, are commonly associated with febrile seizures
in the United States and Asia.
39,40 Fever induced
by viral infection is regulated by components of
the immune response, particularly proinflam-
matory cytokines. Proinflammatory cytokines are
higher in influenza-associated febrile seizures,
further suggesting a causative role for cytokines in
the pathogenesis of febrile seizures. Common
pathogens and causes associated with febrile
seizures are detailed below.
Human herpesvirus-6 (HHV-6) infection
HHV-6 causes exanthema subitum, an acute
febrile illness affecting more than 90% of children
before 2 years of age, the period of greatest
susceptibility to febrile seizures. The incidence of
convulsions among exanthema subitum varies
from 2 to 50%.
35,39,41,42 The incidence of primary
HHV-6 infection is similar between first simple
febrile seizure patients and age-matched controls.
43
HHV-6 DNA, however, is detected more
frequently in CSF of patients with three or more
seizures than those with a single febrile seizure.
44
This finding suggests that HHV-6 may invade the
brain during the acute viremic phase of exanthema
subitum and then reactivate when triggered and
provoke recurrent febrile seizures.
Influenza virus
Influenza virus A is a frequent cause of febrile
seizures in Japan
45 and China.
40 During 1997-1998,
influenza A accounted for 35 - 44% of hospital
admissions for febrile seizures in Hong Kong.
40
Influenza-associated febrile seizures are often pro-
longed and complex, independent of the severity
of the viral infection.
45 IFN- and IL-6 are α
significantly higher in patients with febrile
seizures compared to those without.
46 This finding
suggests that influenza-associated febrile seizures
may be the result of systemic immune responses,
and that IFN- and IL-6 are involved in the α
pathogenesis of febrile seizures (in influenza, at
least).
Vaccines
Vaccines, including measles-mumps-rubella
(MMR) and diphtheria-tetanus-pertussis (DTP),
are associated with an increased risk of febrile
seizures in the first three years of life.
47 MMR-
associated seizures often occur at 7 to 14 days
after vaccination, while DTP-associated seizures
typically occur on the day of vaccination.
48
Children experiencing febrile seizures associated
with vaccination have greater rates of family
history of febrile seizures and a high risk for
recurrent febrile seizures
47,49 Although it remains
unclear whether vaccination itself represents a
risk, or if fever after vaccination is necessary for
seizures, immunization-provoked seizures may
imply a role for systemic inflammation and
genetic susceptibility in the induction of febrile
seizures after vaccination.
Benign afebrile seizures in acute gastroenteritis
Benign seizures associated with diarrheal
illnesses are afebrile generalized tonic-clonic
convulsions that occur between the 1st and the 5th
sick day of viral gastroenteritis in previously
healthy young children 6 months to 3 years of
age.
50 Rotavirus antigen has been detected in the
majority of patients with this condition and
rotaviral RNA has been found in patients' CSF.
51Role of Brain Inflammation in Epileptogenesis
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Rotavirus enterocolitis is the most common
enterocolitis among young children under 2 years
of age. Rotavirus has tropism for astrocytes in
astrocytoma cell lines,
52 and inoculation of
rotavirus strain 2 into the brains of live monkeys
can induce transient symptoms reminiscent of
typical encephalitis (typical infection of the
CNS).
53 Since only 6.4% of children with rotavirus
gastroenteritis present with afebrile benign
seizures,
54 it may be that only a few specific
strains of rotavirus can infect both the CNS and
gastrointestinal system or that host susceptibility
factors make a subset of children more prone
either to CNS invasion by rotavirus or to specific
immune responses to rotavirus.
Medically intractable childhood epilepsy improved
by immunotherapy
Nearly 30% of epilepsy patients are refractory
to conventional anti-epileptic drugs, and many
alternative treatments have been tried to control
epilepsy.
55 Immunotherapy, such as corticosteroids
and ACTH, has been used to treat epilepsy since
ACTH was first reported to have beneficial effects
in the treatment of infantile spasms in 1950.
56 The
mechanism behind the anticonvulsant action of
corticosteroids or ACTH remains elusive. Possibil-
ities include (1) stimulation of glucocorticoid
synthesis that interacts with CNS steroid receptors,
which then influences voltage-dependent calcium
channels; (2) stimulation of neurosteroid synthesis
in glia and neurons that modulate GABAA
receptors; (3) down-regulation of corticotrophin
releasing hormone (CRH) that has proconvulsant
activity in the immature brain; or (4) immuno-
modulation.
57-60
Rasmussen’s encephalitis
Rasmussen's encephalitis is a severe, progres-
sive focal epilepsy of unknown origin that leads
to asymmetric cortical atrophy and deterioration
of motor and cognitive function.
61 The current
histopathological criteria of Rasmussen's encepha-
litis include the presence of T-cell-dominated
inflammation, microglial activation and formation
of microglial nodules, neuronal loss, and as-
trocytic activation. Recently, astrocytic apoptosis
and subsequent loss have been demonstrated as a
specific feature of Rasmussen's encephalitis.
62 A
specific attack by cytotoxic T lymphocytes may be
one possible mechanism responsible for astrocytic
degeneration in Rasmussen's encephalitis.
62
Antibodies to GluR3 have been found in the
serum of some Rasmussen's encephalitis patients,
and repeated plasma exchanges can reduce serum
titers of GluR3 antibodies, decrease seizure fre-
quency, and improve neurologic function.
63
Immunization of animals with GluR3 induces a
disorder resembling the human disease.
63 At the
same time, a recent study reported that anti-
GluR3 antibodies are not specific for Rasmussen's
encephalitis. High antibody titers characterize a
subgroup of non-Rasmussen's encephalitis patients
with "catastrophic" epilepsy and appear to be a
marker for intractable epilepsy not limited to
Rasmussen's encephalitis. Anti-GluR3B peptide
antibodies are significantly associated with seizure
frequency.
29
There is no effective medical treatment for
Rasmussen's encephalitis, except perhaps steroids,
which can be useful when given early in the
course of the disease.
64 A long term follow-up of
11 Rasmussen's encephalitis patients who received
steroids showed that 45% of patients had signifi-
cant improvement of motor function and reduc-
tion of seizure frequency with disappearance of
epilepsia partialis continua, while 55% patients
had no benefit from steroid therapy and ulti-
mately underwent hemispherotomy. Two initial
responders to steroid treatment experienced
progressive recurrence of seizures one to four
years after the discontinuation of steroids and
received a hemispherotomy.
64
Infantile spasms
Infantile spasms are a unique, age-specific
epilepsy of early infancy. The electroencephalogram
(EEG) characteristically shows hypsarrhythmia-
disorganized, chaotic, high voltage polymorphic
delta and theta rhythms with superimposed
multifocal spikes and wave discharges. The onset
of spasms is frequently associated with neuro-
developmental regression. The incidence varies
from 0.25 to 0.60 per 1,000 live births,
65 and the
prevalence rate is 0.15 to 0.2 per 1,000 children
age 10 or younger.
66 Infantile spasms develop in
infants with a variety of CNS pathologies, in-Jieun Choi and Sookyong Koh
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cluding structural abnormalities, prenatal and
postnatal infection, stroke, trauma, and chromo-
somal anomalies.
67 This disease entity of uniform
semiology with diverse causes suggests that in-
fantile spasms are an age-specific but cause-
nonspecific final common response of the brain to
insults.
68,69
ACTH is a well-known effective treatment for
infantile spasms that not only results in seizure
control, but also improves both behavior and
background EEG.
70 Meta-analysis reveals that
ACTH is probably effective for short-term treat-
ment of infantile spasms and leads to resolution
of hypsarrhythmia.
71 Time to response is usually
two weeks. Oral steroids can render 30 to 40% of
patients seizure-free.
72,73 Further, early use of
steroids is more effective; patients treated within
one month of spasm onset had a better outcome
than those treated after more than one month.
74 A
study of 18 children with Down's syndrome and
infantile spasms showed that spasm control was
easier, subsequent seizures were less persistent,
developmental quotients were higher, and a score
of autistic features was lower in children treated
early.
75
Lennox-Gastaut syndrome
Lennox-Gastaut syndrome (LGS) is diagnosed
in children who have a minimum of two seizure
types (usually atonic or astatic (drop) seizures,
nocturnal tonic seizures, and atypical absence
seizures), mental retardation, and bursts of
generalized slow spike-waves on EEG.
76 LGS is
one of the epilepsy syndromes most resistant to
the available antiepileptic medications. Corticos-
teroids and ACTH may be effective in treating
children with LGS.
55 When 10 children with LGS
and intractable seizures were treated with pre-
dnisolone for 12 weeks, 7 achieved seizure freedom
and the other 3 experienced seizure reduction.
77
The patients' clinical improvement was generally
reflected in an improvement in their EEGs.
Another study of 45 children with LGS who
received ACTH for 2 to 8 weeks found that while
51% of patients became seizure free for over 10
days, 78% of these children later relapsed.
78
Landau-Kleffner syndrome (LKS)
Landau-Kleffner syndrome is an acquired
epileptic aphasia presenting as progressive loss of
speech in a previously well child with an abnormal
and usually continuously epileptic EEGs during
slow wave sleep with or without apparent
seizures.
79 There are reports that corticosteroids
improved both clinical features of the syndrome
as well as the EEG, especially when instituted
early.
80,81
Epilepsy with continuous spike wave discharges
(CSWSS)
Continuous spike-waves during slow sleep
syndrome (CSWSS) is a rare, sporadic childhood
epilepsy characterized by the presence of spike-
waves during at least 85% of slow sleep and,
clinically, by the existence of neuropsychological
and behavioral disorders.
82 LKS and CSWSS share
some common features, including first appearance
in childhood and mild epilepsy associated with
severe neuropsychological disturbances. There are
several case reports that CSWSS also responds to
treatment with corticosteroids or ACTH, not only
in terms of seizures and EEG, but also in language
skills.
83
Myoclonic or myoclonic-astatic seizures and other
refractory epilepsies
Myoclonic or myoclonic-astatic seizures have
also been treated with corticosteroids, possibly
because of the frequent daily seizures, acute en-
cephalopathic presentation, medical intractability,
and tendency of the seizures to result in physical
injury. In a study of myoclonic epilepsy, 34
children out of 64 were treated with prednisone
and the remaining 30 children with ACTH.
84
Seizures were effectively controlled in 73% of
children treated with ACTH, but in none treated
with prednisone.
84 In another study of nine
patients with myoclonic epilepsy treated with
steroids, five became seizure free, two showed a
reduction, and the remaining two exhibited no
change.
77 In contrast, only a transient improvement
was reported in 5 of 84 patients with myoclonic
absence epilepsy treated with ACTH.
85 In a study
of children with absence epilepsy, seven were
treated with steroids. All improved and five
became seizure free.
77 In 32 children with intract-
able epilepsy (infantile spasms excluded) treated
with ACTH, 25% of patients became seizure-freeRole of Brain Inflammation in Epileptogenesis
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and 47% showed significant reductions of seizures.
86
SEIZURES CAUSE ACUTE AND
CHRONIC BRAIN INFLAMMATORY
REACTIONS
- Evidence from experimental models of epilepsy
In many animal models of epilepsy, acute
seizures cause glial activation and increased
expression of transcription factors and cytokines
that coordinate inflammatory responses.
87,88 After
status epilepticus, members of the Toll-like
receptor (TLR) family are significantly up-regulated
in the microglia, leading to transcriptional activa-
tion of cytokines, chemokines, MHC class I and II,
and costimulatory molecules.
89 The activated glia
and elevated cytokines, in turn, contribute to
seizure-related hippocampal pathology, such as
neuronal death, neuronal birth, reactive gliosis,
and mossy fiber sprouting.
90-93 Accumulating ex-
perimental data also suggest that seizure-induced
glial activation and up-regulation of pro-inflam-
matory cytokines can lead to neuronal excitability
and neuronal injury either directly, by interacting
with glutamatergic neurotransmission, or in-
directly, by activating gene transcription.
Microglial activation
Microglia are myeloid lineage cells that com-
prise approximately 12% of the brain. Resting
microglia with a ramified morphology are
responsible for immune surveillance
94 and are
activated at a very early stage in response to
injury or immunological stimuli with transfor-
mation to an amoeboid shape.
95 Activated microglia
up-regulate the expression of surface molecules,
such as complement receptors and major histo-
compatibility complex (MHC) molecules, and
release a variety of pro-inflammatory and
cytotoxic soluble factors.
96 MHC class-I and -II,
IL-1, IL-2, IL-6, TGF- 1, the complement com β -
ponents and their receptors, M-CSF, and GM-CSF
are all molecules considered to be signals in the
activation process.
95
Widespread microglial activation accompanied
by neuronal injury occurs after acute seizures.
88,97,98
As a rapid response, activation of microglia may
be responsible for neurodegeneration rather than
a consequence of neurodegeneration. Within four
hours after KA-induced status epilepticus, glial
activation and cytokine expression are found in
the hippocampus (Fig. 1).
99 Neuronal injury is
detected 12- 24 hours following status, many
hours after cytokines are induced in the glia.
99
Status epilepticus, prolonged seizures over 30
minutes, can cause neuronal death
100 through
glutamate-mediated excitotoxicity, necrosis, and
activation of apoptosis.
101 One to three days after
status epilepticus, both neuronal and astrocytic
death are observed in the dentate hilus within the
hippocampus.
102,103 Injured neurons and glia and
their fragmented DNA are rapidly cleared by
activated microglia.
93 The impaired neurogenesis
in inflammation can be effectively restored by
systemic administration of the tetracycline
derivative minocycline, a specific inhibitor of
microglia activation.
104 These findings suggest that
microglial activation associated with inflammation
induces neuronal injury and suppresses neuro-
genesis. The occurrence of spontaneous seizures
has been correlated with the extent of glial activa-
tion, as well as astrocyte and neuron degeneration
in the hippocampus, and blockade of neuronal
death failed to prevent epileptogenesis.
105,106
Cytokines released by microglia influence
astrocytic function and proliferation. Increased
levels of IFN- , IL-1, IL-2, IL-6, TNF- , and M-CSF γ α
are associated with astrogliosis. IL-1Ra, an IL-1
receptor antagonist, is sufficient to prevent astro-
glial proliferation, suggesting a pivotal role of IL-1
in astrocyte activation.
107 In addition, these
cytokines may modulate glutamate homeostasis
by regulating glutamate receptors and trans-
porters in astrocytes.
108,109 Impaired handling of
extracellular glutamate by gliotic astrocytes may
lead to neuroexcitability and excitotoxic neuronal
damages resulting from excessive glutamate
levels.
110 These findings suggest that activation of
microglia and the resultant increase in cytokines
may influence epileptogenesis by altering gluta-
matergic transmission indirectly through modu-
lating astrocytes.
Astrogliosis
For over 100 years, astroglial proliferation hasJieun Choi and Sookyong Koh
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been observed as a pathognomonic finding in
surgically resected hippocampi in patients with
intractable mesial temporal lobe epilepsy. Once
regarded as an inert scar and consequence of the
healing process after neuronal degeneration,
111
recent studies
112,113 suggest that reactive astro-
gliosis and modified astroglial function may have
an important role in the generation and spread of
seizure activity.
Astrocytes are a critical component of the BBB
and have many important roles in glutamate and
potassium uptake and the production of growth
factors, cytokines, and extracellular matrix pro-
teins.
104 In response to immunologic challenges or
brain injuries, astrocytes proliferate and become
hypertrophic and fibrillary. Direct stimulation of
astrocytes by photolysis of caged calcium and
glutamate release in acute seizure models can
induce a paroxysmal depolarization shift (PDS) -
abnormal prolonged depolarization observed
during interictal activity.
112 Cultured astrocytes
isolated from the seizure focus of human epileptic
tissue possess depolarized resting membrane
potentials and are able to generate action potential-
like responses upon injection of current.
113
Astrocytes are initially activated by excessive
neuronal activity, a potent trigger of astrocyte
Ca
2+ signaling. However, once activated, neuronal
firing is no longer needed for continued astroglial
activation. The findings described above suggest
that activated astrocytes in the sclerotic hippo-
campus are not mere bystanders, but active
players in epileptogenesis.
Within 24 to 48 hours after seizure induction,
activation of GFAP-positive astrocytes is noted
throughout the dentate gyrus and hippocampal
Fig. 1. Acute activation of microglia after KA-induced seizures in CX3cr1EGFP/+ transgenic mice. (A) Low magnification
view of a brain section from a Cx3cr1GFP/+ transgenic mouse showing that all parenchymal microglia are fluorescently
labeled green because the Cx3cr1-encoding fractalkine chemokine receptor has been replaced by a green fluorescent protein
(GFP) reporter gene. The box points to massively accumulated microglia one week after KA-induced seizures, likely at the
area of injury, shown in high magnification view (B). High magnification view of PBS control (C) and KA-induced seizures
(D). Within two days after status epilepticus, a nearly two-fold increase in the area of fluorescent cells and significant
microglial proliferation were noted in KA-treated mice compared to control littermates. Note the ramified processes and
apparent increase in the number of GFP+ microglia.Role of Brain Inflammation in Epileptogenesis
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subfields.
107,115 This reactive astrogliosis persists
chronically over three to four months.
105,114,115
Newly generated astrocytes display distinct
changes in glial membrane channels and receptors
to promote neuronal hyperexcitability and seizure
generation. These changes include GluR1 receptors
with elevated flip-to-flop ratios,
116 impaired uptake
of potassium ion due to inwardly rectifying K
+
channels,
117 over-expression of adenosine kinase,
118
and down-regulation of glutamine synthase,
glutamate dehydrogenase, and glial GABA
transporter.
102
Increased inflammation-related gene expression in
the brain after status epilepticus
Gene expression of classical inflammatory
mediators - the complement pathway, cytokines,
and glial markers - is significantly higher in the
hippocampus of both juvenile and adult rats after
KA-induced seizures, based on microarray
analysis in our laboratory (Fig. 2).
119 Inflammation-
related genes were the single most abundant
functional group significantly up-regulated acutely
after seizure, and significant elevations persisted
even 10 days after SE. In juvenile rats, the acute
inflammatory response appears to be part of the
homeostatic response, because there is no cell
death and no recurrent seizures. Experiencing
seizures and an acute inflammatory reaction are
not without consequence, however, and the rats
become permanently more seizure-susceptible. On
the other hand, the inflammatory response in
adult rats appears to be chronic, excessive, and
persistent, and is accompanied by seizure-induced
cell death and subsequent development of
Fig. 2. Time course of changes in expression of select inflammation-related genes significantly regulated in rats after
KA at P15 and P30 compared to controls. Genes (C) for transcription factors known to be early mediators of immune
and inflammation responses, as well as cytokines associated with microglial activation, are rapidly and dramatically
up-regulated after KA-induced seizures at P15 (postnatal day 15; juvenile rats) (A) and P30 (postnatal day 30; adult
rats) (B). Note that some of these inflammation-related genes are increased to a greater extent than at P15 and are
often persistently elevated beyond 72 hours only in adult rats (P30, B) that show seizure-induced cell death and
develop spontaneous recurrent seizures.Jieun Choi and Sookyong Koh
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spontaneous recurrent seizures only in older
animals. Such age-dependent increases are reflected
as microglial activation in the hippocampi.
98,99
Pro-inflammatory cytokines and neuronal
hyperexcitability
Experimentally induced seizures in rodents
trigger a prompt inflammatory response in brain
areas recruited in the onset and propagation of
epileptic activity.
90 Direct intra-cerebral injection of
a cytokine worsens seizure activity,
120,121 and cyto-
kine receptor antibodies, such as IL-1-receptor
antagonist, show powerful anticonvulsant acti-
vity.
122
The mechanisms by which cytokines lead to
neuronal excitability have been explored in several
studies focusing on ictogenic and neurotoxic
properties of IL-1 mediated by IL-1 receptor β
(IL-1RI).
120,123 IL-1RI colocalizes with NMDA
receptors on hippocampal pyramidal neurons,
and IL-1RI-mediated modulation of glutamatergic
transmission may contribute to excitotoxicity and
spontaneous seizures.
124 IL-1 binding to its β
receptor increases NMDA receptor-mediated Ca
2+
influx and surface expression of AMPA recep-
tors.
125,126 IL-1 acts on astrocytes to inhibit β
reuptake of glutamate
127 and increase glutamate
release via TNF- production, α
128 both resulting in
elevated extracellular glutamate levels and hyper-
excitability. Furthermore, IL-1 can stimulate IL-6 β
release.
108 Transgenic mice over-expressing astrocyte
IL-6 show markedly increased astrogliosis and
microgliosis, a loss of inhibitory interneurons, and
are exquisitely and selectively sensitive to gluta-
matergic agonists.
129
Cytokines are involved in the death of neurons.
Direct intraventricular IL-1 injection concurrent β
with brain insult increases injury-induced cell
death and brain edema.
130,131 Inhibition of IL-1
signaling by IL-1 receptor antagonist injection just
prior to chemoconvulsant administration signifi-
cantly attenuates subsequent hippocampal cell
loss, implicating endogenous IL-1 in seizure-
associated cell death.
132
Cytokines can influence the activation of
astrocytes and microglia. Astrogliosis can be
induced in healthy animals by the injection of
cytokines such as IL-1,
133 and injury-induced
microglial activation is suppressed in TNF receptor-
knockout mice.
134 In turn, reactive microglia and
astrocytes themselves provide a rich source of
cytokines after injury or insult, especially IL-6,
TGF- , LIF and IL-1. β
135
Lessons from transgenic mice
Transgenic or knock-out mice technology
provides a powerful tool for studying genetic
control of synaptic excitability and epilepsy. It is
relatively easy to insert, delete, or mutate a gene
of interest or to study the function of spontaneous
mutation of genes causing epilepsy. A chronic
brain inflammatory state has been induced in
transgenic mice overexpressing specific cytokines
to study the functional outcome of inflammatory
mediators in the brain.
Transgenic mice with chronic IL-6 production
from astrocytes using the transcriptional control
of the GFAP promoter display astrogliosis, micro-
gliosis, impaired development of the BBB, and
increased levels of acute-phase proteins and pro-
inflammatory cytokines.
136,137 These mice develop
progressive neurodegeneration in the hippo-
campus and cerebellum, which in turn contributes
to a clinical picture of ataxia, tremor, progressive
learning deficits, hippocampal excitability, and
spontaneous seizures.
137-139 GFAP-IL-6 mice show
markedly enhanced sensitivity to glutamatergic-
induced seizures and lethality, and this may relate
to a compromise of inhibitory paralbumin- or
GABA interneurons.
129
In IL-6 null mice, reactive astrogliosis and
microgliosis are significantly lower after KA-
induced seizure, while morphological hippo-
campal damage, oxidative stress, and apoptotic
neuronal death are greater. IL-6 deficiency
impairs the inflammatory response after KA-
induced seizures and increases neuronal injury.
140
IL-6 is a major inducer of metallothionein I and
II (MT-I+II), antioxidants and neuroregenerative
factors in the CNS.. Decreased MT-I+II levels in
IL-6 null mice may contribute to greater oxidative
stress and cell death. These findings support the
beneficial and protective role of the physiological
inflammatory reaction and caution against
potential exacerbation of neuronal injury by
complete obliteration or blockage of the inflam-Role of Brain Inflammation in Epileptogenesis
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matory cascade.
Transgenic mice deficient in IL-1 receptor 1 β
are resistant to experimental febrile seizure.
Moreover, intracerebral injection of high dose IL-1
, sufficient to generate limbic seizures in wild β
type mice, fails to cause seizures in these mice.38
This finding suggests that IL-1 signaling β
contributes critically to fever-induced hyperexci-
tability underlying febrile seizures and may
provide a link between hyperthermia and genetic
susceptibility to seizure.
Epileptic EL mice, a natural model of human
multifactorial idiopathic epilepsy and complex
partial seizures, experience about 25 - 30 complex
partial seizures with secondary generalization
during routine weekly cage changing. Prior to the
onset of recurrent seizure activity, the number of
GFAP-positive astrocytes is similar in EL and non-
epileptic mice at young ages.
141 Recurrent seizure
activity in EL mice produces a unique type of
gliosis where microglial activation is diffuse and
widespread throughout the cortical surface, in-
cluding the hippocampus, while astrocyte activation
is specifically localized to the hippocampus accom-
panied by down-regulation of glial glutamate
transporters, but without obvious hippocampal
neuronal loss or mossy fiber sprouting.
142,143 These
findings suggest a potential contributory role of
glial abnormalities in the recurrent seizure activity
of human multifactorial idiopathic epilepsy.
INFLAMMATORY REACTIONS IN CHRONIC
EPILEPSY PATIENTS
-Evidence from human epilepsy
Increased expression of proinflammatory mole-
cules has been demonstrated in brain tissue from
patients who received surgery for drug resistant
epilepsies.
99,144-147 Of note, inflammatory reactions
occur not only in classic inflammatory epilepsy
such as Rasmussen's encephalitis, but also in com-
mon intractable epilepsy that does not typically
invoke an inflammatory pathophysiology, such as
temporal lobe epilepsy or tuberous sclerosis. Brain
inflammation may be a common factor contri-
buting or predisposing to the occurrence of seizures
and cell death in various forms of epilepsy of
different etiologies.
148
Blood and CSF from epilepsy patients
Acute inflammatory reaction after seizures has
long been suspected due to clinical observations.
Mean peripheral blood and CSF-leukocyte counts
as well as C-reactive protein, an acute phase
reactant, are significantly elevated in patients who
present with new onset generalized convulsions
without any clinical evidence of CNS or systemic
infection.
10 Involvement of the "cytokine network"
has also been implicated in febrile seizures.
Significantly higher plasma IL-6 levels as well as
a higher ratio of endogenous IL-1 receptor
antagonist to IL-1 are found in children with β
febrile seizures compared to febrile children
without seizures
36 and in epilepsy patients with
recent tonic-clonic convulsions.
149-151
Cytokine gene polymorphism has been linked
to epilepsy susceptibility. The increased frequency
of a biallelic polymorphism in the promoter region
of IL-1 at the -511 position, which is suggested β to
have effects of higher IL-1 production, has been β
reported in patients with temporal lobe epilepsy
with hippocampal sclerosis and prolonged febrile
convulsions.
37 Sporadic simple febrile seizure
patients exhibit significantly higher frequencies of
IL1 -31C/-511T alleles and homozygotes than β
controls.
152 These results suggest that genetic
susceptibility to inflammation may contribute to
epileptogenesis.
Epileptogenic brains of adult epilepsy patients
Active inflammation has been detected not only
in prototypical inflammatory epilepsy such as
Rasmussen's encephalitis or limbic encephalitis,
but also in pharmacoresistant epilepsy of diverse
etiologies. Microglial activation and proliferation
havebeen demonstrated in surgically resected
epileptogenic lesions from adult patients with
chronic intractable epilepsy. In human mesial
temporal lobe epilepsy, activated microglia are
increased over ten fold in the sclerotic hippo-
campi.
153 An abundant population of activated
microglial cells are found in glioneuronal lesions
associated with chronic epileptic activity,
154 in
focal cortical dysplasia
155 and in cortical tubers of
the tuberous sclerosis complex.
146 The duration of
epilepsy and frequency of seizures prior toJieun Choi and Sookyong Koh
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surgical resection significantly correlate with the
density of activated microglia in focal cortical
dysplasia,
155 highly epileptogenic gangliogliomas,
and dysembryoplastic neuroepithelial tumors
(DNET).
154 Activation of microglia appears to be
an important feature of chronic intractable epilepsy,
and microglial proliferation may be functionally
related to epileptogenic brain lesions of diverse
etiology. In addition, pro-inflammatory cytokines,
such as IL-1b and its signaling receptor IL-1R1,
and NF-kB are highly expressed by neurons and
glia in temporal lobe epilepsy,
145 focal cortical
dysplasia,
155 glioneuronal tumors,
154 and tuberous
sclerosis complex.
146 These results strongly support
the involvement of inflammatory and immune
reactions in the pathogenesis of human CNS
disorders associated with epilepsy.
Epileptogenic brains of children with epilepsy
In our laboratory, we quantified cell death,
astrocyte proliferation, microglial activation and
cytokine release in brain cortical tissue from 13
children who underwent epilepsy surgery. Patients
had intractable epilepsies due to focal cortical
dysplasia (6), encephalomalacia (5), Rasmussen's
encephalitis (1), or mesial temporal lobe epilepsy
(1). Five autopsy patients with no history of
seizures or neurological diseases were used as
controls. We found marked glial activation and
neuroinflammation in epileptogenic cortices from
children with intractable epilepsy (Fig. 3). The
majority of our patients had mental retardation.
Numerous fibrillary astrocytes covered the entire
cortex and converged on to blood vessels,
neurons, and microglia. Large numbers of neurons
and astrocytes displayed DNA fragmentation and
the magnitude significantly correlated with seizure
frequency. Panlaminar astrocytosis, diffuse
microglial activation, and release of proinflam-
matory cytokines, especially IL-1 , IL-8, IL-12p70 β
and MIP-1 , were present in the epilep β togenic
cortices, consistent with chronic neuroinflam-
matory responses. IL-6 and MCP-1 were
significantly higher in patients with a family
history of epilepsy, suggesting links between
genetic susceptibility to inflammation and epilepsy.
Our results also suggest that active neuroinflam-
mation occurs in pediatric epilepsy and may play
a common pathogenic role in childhood epilepsies
of diverse etiologies.
CONCLUSION
Accumulating evidence suggests that inflam-
matory and immune reactions may play an
important role in neuronal excitability and
Fig. 3. Triple immunofluorescence confocal images of neurons, microglia, and astrocytes in the epileptogenic cortex
of patients with chronic intractable childhood epilepsy. (A) Activated microglia (blue) and astrocytes (red) are found
in close contact with each other and with neurons (green). Bar = 100 m. (B) Microglial processes (red) wrap around μ
a neuron (green), engulfing fragmented DNA (blue). Bar = 10 m. μRole of Brain Inflammation in Epileptogenesis
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epileptogenesis. Chronic brain inflammation may
also contribute to intractability of seizures and
comorbidity in chronic epilepsy patients. No
effective treatments currently exist to protect the
brain from seizure-induced cell death and prevent
future development of chronic epilepsy. Modula-
tion of inflammatory reactions in the brain and
targeting of inflammatory mediators may be
effective therapeutic strategies to prevent or limit
epileptogenesis in the vulnerable nervous system.
Anti-inflammatory therapy may be particularly
helpful when given during the latency period
shortly after the initial neurologic insult, but prior
to the onset of epilepsy, before permanent
changes can occur in neuronal aggregates that
promote hyperexcitability and seizure spread. The
causative role of inflammation in the pathogenesis
of epilepsy and neurological sequelae of chronic
intractable epilepsy needs to be proven and
requires further investigation from both clinical
and basic science angles.
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